MSTN
ENSG00000138379
Target class
Secreted protein
Chromosome
2
Approved drugs
0
Clinical candidates (approved and in development)
6
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- MSTN
- Gene name
- Myostatin
- Gene symbol
- MSTN
- Previous gene symbols
- GDF8
- Protein name
- Growth/differentiation factor 8 (GDF-8) (Myostatin)
- Gene biotype
- Protein coding
- Gene family
- Transforming growth factor beta superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 11
- Highest tissue expression
- 3.88
- Tissue specificity (Gini)
- 0.373
- Tissue specificity (tau)
- 0.811
- KEGG gene identifiers
- hsa:2660
- Reactome pathways
- R-HSA-9617828
- Protein interaction confidence
- 0.841294
- Protein interaction partners
- 34
- End position
- 190062729
- Start position
- 190055700
- Chromosome
- 2
- Strand
- Reverse
- Secreted .
- Tissue specificity (tau)
- 0.81098
- Expression inequality (Gini)
- 0.373095
Expression in transcripts per million
- Cervix - Ectocervix
- 3.88
- Cervix - Endocervix
- 2.47
- Nerve - Tibial
- 1.69
- Brain - Cerebellum
- 1.67
- Cells - Cultured fibroblasts
- 1.53
Expression in transcripts per million
- Cervix - Ectocervix3.88
- Cervix - Endocervix2.47
- Nerve - Tibial1.69
- Brain - Cerebellum1.67
- Cells - Cultured fibroblasts1.53
- Artery - Aorta1.46
- Adrenal Gland1.37
- Pituitary1.32
- Muscle - Skeletal1.29
- Brain - Cerebellar Hemisphere1.25
- Uterus1.05
- Colon - Sigmoid0.96
- Thyroid0.92
- Ovary0.92
- Vagina0.92
- Fallopian Tube0.87
- Brain - Hypothalamus0.87
- Adipose - Subcutaneous0.86
- Artery - Coronary0.82
- Testis0.74
- Prostate0.73
- Brain - Cortex0.73
- Breast - Mammary Tissue0.72
- Brain - Amygdala0.72
- Brain - Nucleus accumbens (basal ganglia)0.7
And 29 more, listed on the interactive page.
- GO:0007517
- GO:0045662
- GO:0045893
- GO:0046716
- GO:0048632
- GO:0051898
- GO:0061450
Cellular components
- GO:0005576
- GO:0005102
- GO:0005125
- GO:0005515
- GO:0008083
- GO:0042802
Related records
Trials (30)
- A Dose-Escalation Study in Participants With Advanced Cancer
- A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
- A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
- A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
- A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
- A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
- A Study in Older Participants Who Have Fallen and Have Muscle Weakness
- A Study of LY2495655 in Healthy Subjects
- A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
- A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
- A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
- A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
- An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
- An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
- EAP of Apitegromab for Patients With Spinal Muscular Atrophy
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
- Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Drugs (6)
- Apitegromab Growth/differentiation factor 8 inhibitor
- Domagrozumab Growth/differentiation factor 8 inhibitor
- Landogrozumab Growth/differentiation factor 8 inhibitor
- Ramatercept Growth/differentiation factor 8 inhibitor
- Stamulumab Growth/differentiation factor 8 inhibitor
- Trevogrumab Growth/differentiation factor 8 inhibitor